Parker Bioscience will expand laboratory, cleanroom, office, and warehouse facilities at its Birtley, UK manufacturing site.
Parker Bioscience will undertake a multi-million-dollar phased-investment program throughout the remainder of 2018 to expand laboratory, cleanroom, office, and warehouse facilities at its Birtley, UK manufacturing site, the company announced on May 16, 2018.
In 2017, it was announced that the Birtley facility would start the manufacture of the company’s automated bioprocessing systems, complementing existing production at its site in California. In 2016, the company introduced a new ISO Class 7 cleanroom at the facility, from which Parker Bioscience is now producing single-use manifolds incorporating tubing, bioprocess containers, filters, sensors, and other components for use in the bioprocessing industry.
The increased investment will enable Parker Bioscience to service its European biopharmaceutical markets more effectively by shortening the supply chain.
Source: Parker Bioscience
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.